動物用藥品製劑市場－全球產業規模、佔有率、趨勢、機會與預測：按產品、動物種類、給藥途徑、地區和競爭格局分類，2021-2031年

全球動物用藥品製劑市場預計將從 2025 年的 17.7 億美元成長到 2031 年的 28.6 億美元，複合年成長率為 8.33%。

在這個專業領域，持有執照的專業人員會配製藥物成分，並在已通過核准藥物無法使用或不適用時，為動物生產定製藥物。市場成長的主要驅動力是伴侶動物醫療化程度的提高，以及臨床上對物種特異性劑型和調味劑的需求，以確保治療依從性。這並非暫時的市場波動，而是畜牧養殖戶和寵物飼主對獸醫護理標準持續提升的標誌。

阻礙市場發展的一大障礙是對藥品原料藥監管力道的加強。這給藥店帶來了沉重的合規責任，並限制了某些處方藥的取得。儘管面臨這些監管挑戰，但由於消費者在動物保健方面的持續支出，該行業的經濟基礎仍然穩固。根據美國寵物用品協會（APPA）的數據，2024年美國獸醫保健支出和產品銷售額將達398億美元。如此龐大的支出凸顯了市場的永續性以及對個人化動物醫藥醫療的持續需求。

市場促進因素

市售獸藥的停產和供不應求正成為全球動物用藥品配製市場的主要動力，造成亟需的治療缺口，而這一缺口只能透過定製藥物來填補。隨著製藥公司停止生產盈利的過時藥物，並面臨嚴重的供應鏈中斷，獸醫越來越依賴藥局來確保基本治療的持續性。隨著臨床需求和市售藥物供應缺口的擴大，這種依賴性也不斷增強。根據加拿大獸醫協會 (CVMA) 2025 年 11 月發布的一份報告，加拿大獸醫將發現他們之前使用的藥物中有 40% 幾乎無法獲得，這將使配製行業從輔助服務轉變為預防因生產不穩定而導致的動物健康問題的關鍵基礎設施。

同時，寵物擁有率的上升以及人們對伴侶動物日益人性化的認知，從根本上改變了藥物需求的規模和複雜性。飼主將寵物視為家庭成員，他們越來越需要先進的治療方法和物種特異性製劑，例如經皮凝膠和調味液體，以確保遵守用藥並提高寵物的生活品質。這種文化演變體現在擁有寵物的家庭數量的顯著成長。根據澳洲動物醫學會2025年9月發布的報告，全國73%的家庭將擁有寵物。這一人口趨勢為動物保健產業提供了強勁的經濟基礎，碩騰公司（Zoetis）的業績也印證了這一點。該公司在2025年11月公佈的第三季銷售額為24億美元，主要得益於對伴侶動物療法的持續需求。

市場挑戰

全球動物用藥品配製市場發展面臨的主要障礙之一是對原料藥）使用日益嚴格的監管。監管機構正在執行嚴格的指導方針，限制藥劑師使用原料藥​​配製藥物，並強制要求優先使用FDA核准的商業產品，即使這些產品並非特定動物病情的最佳選擇。這種監管立場對市場成長構成重大阻礙，迫使藥局承擔高昂的營運成本和行政負擔以證明其合規性。因此，許多機構被迫縮減產品線，甚至完全退出獸藥領域，導致客製化獸藥的整體供應量下降。

這種限制性環境嚴重阻礙了市場應對供應鏈短缺的能力。例如，美國藥局配藥聯盟 (Alliance for Pharmacy Compounding) 2024 年的一項調查發現，28% 的受訪藥局正在專門配製阿莫西林懸浮液，以緩解市售產品的短缺。當法規限制原料的使用時，應對此類關鍵短缺所需的柔軟性就會喪失。強制執行這些嚴格的限制會在行業內造成瓶頸，使其無法充分擴大定製藥品的供應規模，以滿足獸醫和畜牧養殖戶不斷變化的需求，最終阻礙整個市場的成長。

市場趨勢

隨著獸醫在傳統藥品分發監管日益嚴格的情況下尋求合規庫存管理的方法，503B外包設施（專門為獸醫診所提供庫存管理服務）的成長正在顯著改變供應鏈。與僅限於患者特定處方箋的503A藥房不同，503B設施按照聯邦藥品生產品質管理規範（cGMP）運營，能夠生產保存期限長的散裝製劑，供診所合法儲存以備即時使用。這種結構性變革正在推動對設施改善的資本投資，以滿足對標準化、受監管動物醫藥日益成長的需求。正如俄亥俄州就業局在2024年9月報導的那樣，韋奇伍德俄亥俄州公司宣布投資550萬美元擴建其已在FDA註冊的503B外包設施，以增強其對這些重要散裝製劑的生產和供給能力。

同時，透過策略併購的市場整合正在加速推進，主要企業不斷吸收專業知識並拓展其地域覆蓋範圍。主要企業正在收購本地藥局和技術平台，以確保在分散的藥局市場中佔據更大的佔有率，並最佳化其在獸藥和人用藥領域的運作。這種整合使企業能夠享受規模經濟效益，同時擴展其業務範圍，將危險品、無菌和非無菌配製服務納入單一組織。這一趨勢在近期的幾項重大交易中均有所體現。例如，根據DVM360在2024年12月報道，Greywolf Animal Health以2,250萬美元收購了曼尼托巴省的Compounding Pharmacy，以加強其藥房部門並拓展其在加拿大市場的服務能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：動物用藥品配製全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類別（抗感染劑、抗發炎藥、荷爾蒙及其替代品、中樞神經系統藥物、其他）
  • 動物種類（伴侶動物、家畜）
  • 給藥途徑（口服、注射、外用、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美動物用藥品配製市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲動物用藥品配製市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區動物用藥品配製市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲動物用藥品配製市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲動物用藥品配製市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球動物用藥品配製市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Animal Drug Compounding Market is projected to expand from USD 1.77 Billion in 2025 to USD 2.86 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.33%. This specialized sector involves licensed professionals manipulating pharmaceutical ingredients to produce customized medications for animals when approved commercial drugs are unavailable or inappropriate. The market's upward trajectory is primarily sustained by the growing medicalization of companion animals and the clinical requirement for dosage forms and flavorings tailored to specific species to guarantee treatment compliance. Rather than representing fleeting market shifts, these factors signify a lasting advancement in the veterinary care standards demanded by livestock producers and pet owners alike.

One significant obstacle hindering market progression is the heightened regulatory oversight concerning bulk drug substances, which places heavy compliance responsibilities on compounding pharmacies and restricts access to specific preparations. Despite these regulatory difficulties, the industry's economic base remains strong, supported by persistent consumer spending on animal health. Data from the American Pet Products Association indicates that expenditures on veterinary care and product sales in the United States reached $39.8 billion in 2024. This significant financial dedication highlights the market's durability and the ongoing need for personalized veterinary pharmacotherapy.

Market Driver

The discontinuation and shortage of commercial veterinary drugs act as primary catalysts for the Global Animal Drug Compounding Market by generating urgent therapeutic gaps that only customized medications can bridge. As pharmaceutical companies cease production of older, less profitable drugs or face significant supply chain obstacles, veterinarians increasingly depend on compounding pharmacies to ensure continuity of care for essential treatments. This dependency is growing as the disparity between clinical necessities and commercial availability widens. According to the Canadian Veterinary Medical Association in November 2025, veterinarians in Canada have effectively lost access to 40% of the medications formerly used for patient care, transforming the compounding sector from an auxiliary service into a vital infrastructure that prevents manufacturing instability from compromising animal health.

Concurrently, the increasing rates of pet adoption and the humanization of companion animals are fundamentally changing the scale and intricacy of pharmaceutical requirements. Owners who regard their pets as essential family members are seeking sophisticated medical treatments and species-specific formulations, such as transdermal gels or flavored liquids, to enhance adherence and quality of life. This cultural evolution is reflected in significant ownership growth, with Animal Medicines Australia reporting in September 2025 that pet ownership has risen to include 73% of households nationally. This demographic trend underpins a robust economic landscape for animal health, further demonstrated by Zoetis Inc., which reported third-quarter revenue of $2.4 billion in November 2025 due to enduring demand for companion animal therapies.

Market Challenge

The central hurdle obstructing the Global Animal Drug Compounding Market's development is the escalating regulatory scrutiny surrounding the utilization of bulk drug substances. Authorities are rigorously implementing guidelines that restrict pharmacists from compounding medications using bulk active ingredients, mandating a preference for FDA-approved commercial products even if those options are not the ideal fit for a specific animal's condition. This regulatory stance creates a significant impediment to market growth, as compounding pharmacies are forced to absorb higher operational expenses and administrative tasks to demonstrate compliance. Consequently, numerous facilities are compelled to limit their product ranges or withdraw from the animal health sector entirely, thereby diminishing the overall accessibility of customized veterinary medications.

This constrained environment significantly hampers the market's capacity to react to supply chain deficiencies. For example, the Alliance for Pharmacy Compounding reported in 2024 that 28% of surveyed compounding pharmacies prepared amoxicillin suspension explicitly to alleviate commercial shortages. When regulations restrict the use of bulk substances, they reduce the flexibility needed to manage such critical shortfalls. By enforcing these strict boundaries, the industry encounters a bottleneck where the provision of tailored medications cannot sufficiently expand to satisfy the changing requirements of veterinarians and livestock producers, ultimately stagnating the market's broader expansion.

Market Trends

The growth of 503B outsourcing facilities dedicated to office-use stock is profoundly transforming the supply chain, as veterinarians search for compliant methods to sustain inventory amidst stricter regulations on traditional compounding. In contrast to 503A pharmacies, which are limited to patient-specific prescriptions, 503B facilities function under federal Good Manufacturing Practices (cGMP), enabling the production of bulk preparations with longer shelf lives that clinics can legally stock for immediate use. This structural evolution is prompting capital investment into facility improvements to satisfy the rising demand for standardized, compliant veterinary drugs. As reported by JobsOhio in September 2024, Wedgewood Connect Ohio declared a capital investment of $5.5 million to enlarge its FDA-registered 503B outsourcing facility, thereby enhancing its capacity to manufacture and supply these essential bulk formulations.

At the same time, market consolidation driven by strategic mergers and acquisitions is gaining momentum as leading competitors absorb specialized capabilities and extend their geographic reach. Dominant firms are purchasing regional pharmacies and technology platforms to secure a greater portion of the fragmented compounding market and optimize operations across both veterinary and human sectors. This aggregation enables companies to exploit economies of scale while broadening their portfolios to encompass hazardous, sterile, and non-sterile compounding services within a single entity. This trend is illustrated by recent significant transactions; for example, DVM360 reported in December 2024 that Grey Wolf Animal Health Corp acquired the Compounding Pharmacy of Manitoba for $22.5 million to strengthen its pharmacy division and widen its service capabilities in the Canadian market.

Key Market Players

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

Report Scope

In this report, the Global Animal Drug Compounding Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Drug Compounding Market, By Product

• Anti-infective Agents
• Anti-inflammatory Agents
• Hormones & Substitutes
• CNS Agents
• Others

Animal Drug Compounding Market, By Animal Type

• Companion Animal
• Livestock Animal

Animal Drug Compounding Market, By Route of Administration

• Oral
• Injectable
• Topical
• Others

Animal Drug Compounding Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Drug Compounding Market.

Available Customizations:

Global Animal Drug Compounding Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Drug Compounding Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, Others)
  • 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
  • 5.2.3. By Route of Administration (Oral, Injectable, Topical, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Animal Drug Compounding Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Drug Compounding Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Animal Drug Compounding Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Animal Drug Compounding Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration

7. Europe Animal Drug Compounding Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Drug Compounding Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. France Animal Drug Compounding Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. United Kingdom Animal Drug Compounding Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. Italy Animal Drug Compounding Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Animal Drug Compounding Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Animal Drug Compounding Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Drug Compounding Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Animal Drug Compounding Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Animal Drug Compounding Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Animal Drug Compounding Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Animal Drug Compounding Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Animal Drug Compounding Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Drug Compounding Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. UAE Animal Drug Compounding Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. South Africa Animal Drug Compounding Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration

10. South America Animal Drug Compounding Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Drug Compounding Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Colombia Animal Drug Compounding Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. Argentina Animal Drug Compounding Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Drug Compounding Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Wedgewood Village Pharmacy, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Vimian Group AB
• 15.3. Pharmaca Health Intelligence Ltd
• 15.4. Akina Animal Health
• 15.5. Triangle Compounding Pharmacy
• 15.6. Davis Islands Pharmacy & Compounding Lab
• 15.7. Custom Med Compounding Pharmacy
• 15.8. Central Compounding Center South
• 15.9. Wellness Compounding Pharmacy of Cary
• 15.10. Millers Pharmacy

16. Strategic Recommendations

17. About Us & Disclaimer